Bernard Escudier

Active 1991–2026

251
Papers
80,716
Citations
121
h-index
248
i10-index

Citations

Citations per year for Bernard Escudier1956: 2 citations1993: 2 citations1994: 1 citations1995: 1 citations1996: 3 citations1997: 5 citations1998: 11 citations1999: 12 citations2000: 30 citations2001: 17 citations2002: 41 citations2003: 36 citations2004: 82 citations2005: 100 citations2006: 171 citations2007: 238 citations2008: 326 citations2009: 424 citations2010: 465 citations2011: 499 citations2012: 512 citations2013: 608 citations2014: 535 citations2015: 490 citations2016: 650 citations2017: 753 citations2018: 947 citations2019: 3,029 citations2020: 3,669 citations2021: 3,508 citations2022: 2,770 citations2023: 2,044 citations2024: 2,964 citations2025: 1,369 citations2026: 45 citations1957–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,254 citing papers, 23.2% of this breakdownChina: 3,879 citing papers, 14.4% of this breakdownFrance: 1,634 citing papers, 6% of this breakdownItaly: 1,573 citing papers, 5.8% of this breakdownUnited Kingdom: 1,394 citing papers, 5.2% of this breakdownGermany: 1,161 citing papers, 4.3% of this breakdownJapan: 1,012 citing papers, 3.7% of this breakdownCanada: 970 citing papers, 3.6% of this breakdownSpain: 799 citing papers, 3% of this breakdownNetherlands: 660 citing papers, 2.4% of this breakdownAustralia: 643 citing papers, 2.4% of this breakdownSwitzerland: 530 citing papers, 2% of this breakdown
0%23.2%Other 24%

Fields

  • Medicine57.9%
  • Biochemistry, Genetics and Molecular Biology31.1%
  • Immunology and Microbiology7.6%
  • Engineering0.7%
  • Neuroscience0.3%
  • Materials Science0.3%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers10%
  • Renal cell carcinoma treatment6.3%
  • Gut microbiota and health3.8%
  • Immunotherapy and Immune Responses3.6%
  • Extracellular vesicles in disease3%
  • Immune Cell Function and Interaction2.7%
  • Other70.6%

Coauthors

All papers

Open in search
  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Benoît Quinquis, Nicolas Pons, Bernhard Ryffel, Véronique Minard-Colin, Patrick Gonin, Jean‐Charles Soria, Éric Deutsch, Yohann Loriot, François Ghiringhelli, Gérard Zalcman, François Goldwasser, Bernard Escudier, Matthew D. Hellmann, Alexander Eggermont, Didier Raoult, Laurence Albigès, Guido Kroemer, Laurence Zitvogel - Science 2017 cited by 5,594

  2. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 cited by 4,643

  3. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 5,890

  4. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert J. Motzer - New England Journal of Medicine 2021 cited by 1,746

  5. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Translational Medicine 2005 cited by 1,259

  6. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregg Fine, Thomas Powles - Nature Medicine 2018 cited by 1,250

  7. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , - Annals of Oncology 2014 cited by 2,259

  8. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , - Annals of Oncology 2019 cited by 1,159

  9. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , - Annals of Oncology 2018 cited by 871

  10. Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Edoardo Pasolli, Nicola Segata, Carlos López-Otı́n, Zoltán Szállási, Fabrice André, Valerio Iebba, Valentin Quiniou, David Klatzmann, Jacques Bou Khalil, S. Khelaifia, Didier Raoult, Laurence Albigès, Bernard Escudier, Alexander Eggermont, Fathia Mami‐Chouaib, Paola Nisticò, François Ghiringhelli, Bertrand Routy, Nathalie Labarrière, Vincent Cattoir, Guido Kroemer, Laurence Zitvogel - Science 2020 cited by 384

  11. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2020 cited by 561

  12. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernard Escudier, Guido Kroemer, Laurence Albigès, Laurence Zitvogel - European Urology 2020 cited by 377

  13. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marjorie C. Green, Robert J. Motzer - The Lancet 2019 cited by 1,010

  14. Renal cell carcinoma

    Authors: , , - The Lancet 2009 cited by 1,633

  15. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Éric Deutsch, Karla A. Lee, Laura A. Bolte, Johannes R. Björk, Rinse K. Weersma, Fabrice Barlési, Lucas Padilha, Ana Finzel, Morten L. Isaksen, Bernard Escudier, Laurence Albigès, David Planchard, Fabrice André, Chiara Cremolini, Stéphanie Martinez, Benjamin Besse, Liping Zhao, Nicola Segata, Jérôme Wojcik, Guido Kroemer, Laurence Zitvogel - Cell 2024 cited by 181

  16. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer 2022 cited by 263

  17. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 cited by 307

  18. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780

  19. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 939

  20. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 1,226

  21. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 940

  22. Malignant effusions and immunogenic tumour-derived exosomes

    Authors: , , , , , , , , , , , , , , - The Lancet 2002 cited by 940

  23. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nizar M. Tannir - Cancer 2020 cited by 337

  24. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2022 cited by 142